joining the club

TMC approves the addition of the University of Houston's new medical school

UH's College of Medicine is the newest addition to the Texas Medical Center. Photo courtesy of University of Houston

The largest medical city in the world has a new resident. The University of Houston College of Medicine is the newest official member of the Texas Medical Center (TMC). The move comes following approval by the TMC board of directors, UH announced.

This addition, which is Houston's first new medical school in nearly 50 years, means potential collaboration with dozens of hospitals and academic institutions, including four other medical schools.

UH's new College of Medicine was found to specifically serve underserved communities in Houston and across Texas. To address a critical statewide shortage of primary care doctors, the UH College of Medicine emphasizes primary care, especially in urban and rural communities, which often have poorer health outcomes, a press release notes. The inaugural class launched in fall 2020 with some 30 medical students.

TMC named the University of Houston a member institution in 2009; the school's College of Pharmacy has been a member since 1980.

A new three-story, 130,000-square-foot College of Medicine building is currently under construction on the UH campus, with a summer 2022 opening date. The facility will be located on 43-acres and will feature modern classroom and meeting spaces, state-of-the-art anatomy and simulation suites, and more, per UH.

Unofficially dubbed "Medical City," the Medical Center sees more than 10 million patients per year, employs more than 106,000 total workers, and is home to the world's largest children's hospital (Texas Children's Hospital), and cancer hospital (MD Anderson Cancer Center).

"We are elated to join the Texas Medical Center as a member institution and look forward to engaging with colleagues at other institutions to advance clinical issues and best practices, and further joint research endeavors," said Dr. Stephen Spann, founding dean of the UH College of Medicine and new member of the TMC Advisory Board, in a statement. "The tragedy of the COVID-19 pandemic has paradoxically produced an opportunity to address larger issues facing our health care systems, such as health equity. Together with our TMC partners, we can help be part of the solution."

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Houston-based Soliton, which has created a technology that uses sound to treat cellulite and scars, has been acquired. Photo via soliton.com

A California company has acquired Houston-based Soliton as well as its innovative device that uses sound to eliminate cellulite.

Allergan Aesthetics, an AbbVie company, has announced an agreement to acquire Soliton and its rapid acoustic pulse device RESONICTM, which recently received U.S. Food and Drug Administration clearance for the treatment of cellulite.

The company's team first developed the basis of the tool for tattoo removal and earned FDA clearance for that treatment a few years ago. Christopher Capelli and Walter Klemp co-founded Soliton in 2012.

The acquisition will take Soliton's technology to the next level, says Klemp, who serves as the company's executive chairman.

"Allergan Aesthetics' brand recognition, global footprint, track record and commitment to developing best-in-class aesthetic treatments makes the Company ideally suited to maximize the commercial potential of the RESONICTM rapid acoustic pulse technology," Klemp says in the release.

"I am proud of the passion and accomplishments of the Soliton team and thankful for the ongoing support of our investors which have culminated in this transaction," he continues. "We look forward to working with Allergan Aesthetics to ensure a successful completion of this transaction."

For Carrie Strom, president of Global Allergan Aesthetics and senior vice president at AbbVie, Soliton's solution has a great potential in the market. Soliton's clinical trial data that was submitted to the FDA showed that after a single treatment session, RESONICTM demonstrated significant improvement and strong patient satisfaction with 92.9 percent of subjects agreeing or strongly agreeing their cellulite appeared improved, per the release.

"There is a huge unmet need to address cellulite and effective treatments have been elusive and frustrating for consumers," Strom says in the release. "Soliton's technology offers a new, completely non-invasive approach with clinically-proven results to reduce the appearance of cellulite with no patient downtime.

"The addition of this technology complements Allergan Aesthetics' portfolio of body contouring treatments," she continues. "Health care providers will now have another option to address consumers' aesthetic concerns."

Brad Hauser, CEO of Soliton, previously told InnovationMap that the company's plans for 2021 included focusing on the commercialization of their product and get it into the hands of dermatologists, plastic surgeons, and other medical professionals for 25 key accounts — potentially including ones Houston — with a plan for a national rollout in 2022.

Trending News